Donate For Public and Patients Store Search

F124 - Hand and Foot Psoriasis, Dermatitis, and Other Inflammatory Dermatoses

Monday, March 4; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • 1. Identify and diagnose common inflammatory hand and foot inflammatory dermatoses including psoriasis, irritant and allergic contact dermatitis and palmo-plantar pustulosis
  • 2. Identify which patients with hand and foot inflammatory dermatoses should be patch tested and use the proper allergens and series
  • 3. Use evidence-based data to select the best treatment options (including topical, phototherapy and systemic therapy) for hand and foot psoriasis, dermatitis and palmo-plantar pustulosis

Description

Common inflammatory dermatoses such as psoriasis, atopic dermatitis and contact dermatitis often involve hands and feet. The morphology of many of these dermatoses is different on palms and soles, making the diagnosis more challenging. In addition, inflammatory conditions involving palms and soles often do not respond as well to topical and systemic treatments. This session will review the different clinical presentations of common hand and feet dermatoses and the role of patch testing. The focus will be on the management of hand and foot psoriasis, dermatitis and palmo-plantar pustulosis. Recent data on the efficacy of biological agents and oral systemic agents and will be reviewed and discussed.

Disclosures

  • Bissonnette, Robert, MD, MSc: AbbVie – I(Grants/Research Funding); Bausch Health – C(H); BMS – A(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), I(Grants/Research Funding); Boston Pharmaceuticals – C(H); Dermavant Sciences – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), I(Grants/Research Funding); Escalier – I(Grants/Research Funding); Janssen-Ortho Inc. – C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Sienna Biopharmaceuticals – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding);
  • Cohen, David Eric, MD: Bickel Biotechnology – B(SO); Celgene – A(H); Cutanea Life Sciences – A(H); Dermira – B(Fees), B(ST); Facilitation of International Dermatology Education – C(H); Ferndale Laboratories, Inc. – C(H); Ferrer – A(H); Kadmon Corporation, LLC – B(Fees); Medimetriks Pharmaceuticals, Inc. – C(H), C(SO); Novartis – C(H);
  • Guttman, Emma, MD, PhD: AbbVie – C(H), I(Grants/Research Funding); Almirall – A(H), C(H), I(Grants/Research Funding); Amgen – C(H), I(Grants/Research Funding); AnaptysBio – I(Grants/Research Funding); Asana Biosciences, LLC – A(H), C(H), I(Grants/Research Funding); Boehringer Ingelheim – A(H), C(H), I(Grants/Research Funding); Cara Therapeutics – A(H), C(H); Celgene Corporation – A(H), C(H), I(Grants/Research Funding); Concert Pharmaceuticals – C(H), I(Grants/Research Funding); DBV Technologies – A(H), C(H); Dermavant Sciences – A(H), I(Grants/Research Funding); Dermira – A(H), C(H), I(Grants/Research Funding); DS Biopharma – C(H), I(Grants/Research Funding); Eli Lilly and Company – A(H), C(H), I(Grants/Research Funding); EMD Serono – C(H); Escalier – A(H), C(H); FLX Bio – C(H); Galderma Research & Development, LLC – A(H), C(H), I(Grants/Research Funding); Glenmark Generics Inc. – A(H), C(H), I(Grants/Research Funding); Incyte Corporation – A(H); Innovaderm Research Inc. – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Kiniksa Pharmaceuticals, Ltd. – I(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – A(H), C(H), I(Grants/Research Funding); Leo Pharma Inc – A(H), C(H), I(Grants/Research Funding); Mitsibushi Pharma – C(H); Novan – A(H), I(Grants/Research Funding); Novartis – A(H), C(H), I(Grants/Research Funding); Pfizer Inc. – A(H), C(H), I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – A(H), C(H); Regeneron Pharmaceuticals, Inc. – I(Grants/Research Funding); Sanofi – A(H), C(H); Sienna Biopharmaceuticals – A(H), C(H), I(Grants/Research Funding); UCB – I(Grants/Research Funding); Union Therapeutics – C(H), I(Grants/Research Funding);
  • Strober, Bruce Elliot, MD, PhD: AbbVie – A(H), C(H), I(NC), O(NC); Affibody – C(Fees); Almirall – C(H); Amgen – C(H), I(NC); Arena Pharmaceuticals – C(Fees); Boehringer Ingelheim – C(H), I(NC); Bristol-Myers Squibb – A(H), C(Fees); Celgene Corporation – A(H), C(H), I(NC); Dermavant Sciences, Inc. – C(Fees); Dermira – A(H), C(H); Eli Lilly and Company – A(H), C(H), I(NC); Galderma Research & Development, LLC – I(NC); GlaxoSmithKline – C(H); Janssen-Ortho Inc. – A(H), C(H), I(NC), O(NC); Leo Pharma Inc – C(H); Meiji Seika Pharma Co., Ltd – C(Fees); Menlo Therapeutics – C(H); Merck & Co., Inc – I(NC); Novartis Pharmaceuticals Corp. – A(H), C(H); Ortho Dermatologics – C(H); Pfizer Inc. – A(H), C(H), I(NC); Sanofi/Regeneron – A(H), C(H); Sun Pharmaceutical Industries Ltd. – A(H), C(H), I(NC); UCB – A(H), C(Fees);
Schedule
Monday, March 4
1:00 PM
All faculty / Hand and Foot Psoriasis and Other Inflammtory Dermatoses
Event Details
  • Date
    Monday, March 4
  • Time
    1:00 PM - 3:00 PM
  • Location
    Room 206
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Robert Bissonnette, MD, MSc, FAAD
Speakers
  • Bruce Elliot Strober, MD, PhD, FAAD
  • David Eric Cohen, MD, FAAD
  • Emma Guttman, MD, PhD, FAAD - Handout